Browse the evidence

Acai supplementation increased Trolox-equivalent antioxidant capacity (TEAC) by 11% after 24 hours compared to placebo.

Acai supplementation may enhance antioxidant capacity in men post-exercise.

Diabetic nephropathy significantly increases cardiovascular risk.

Monitoring cardiovascular health is crucial for T2D patients with diabetic nephropathy.

The Open Formulary group had a mean reduction in A1c of −2.7 ± 2.4, which was significantly greater than the Restrictive Formulary group's reduction of −0.74 ± 2.1.

Practitioners may consider that an open formulary can lead to better glycemic control in patients with type 2 diabetes.

The association between adiposity and cardiovascular events is linear above specific BMI thresholds.

Understanding BMI thresholds can help in assessing cardiovascular risk.

The most common adverse events with tirzepatide were gastrointestinal, primarily mild to moderate in severity.

Practitioners should monitor for gastrointestinal side effects in patients using tirzepatide.

Gastrointestinal adverse events were reported in 79.6% of the cagrilintide-semaglutide group and 39.9% in the placebo group.

Clinicians should monitor for gastrointestinal side effects in patients receiving cagrilintide-semaglutide.

Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).

Clinicians should monitor for gastrointestinal side effects in patients taking oral semaglutide.

Gastrointestinal adverse effects were the most commonly reported side effects of retatrutide.

Clinicians should monitor for gastrointestinal side effects in patients treated with retatrutide.

The most common adverse events in the retatrutide groups were gastrointestinal and were mostly mild to moderate in severity.

Practitioners should monitor for gastrointestinal side effects in patients treated with retatrutide.

About 14% caloric restriction for 2 years in healthy humans improved thymopoiesis.

Caloric restriction may enhance immune function in healthy individuals.

Resmetirom achieved resolution of steatohepatitis without worsening of fibrosis in 26%-30% of participants compared to 10% for placebo.

Resmetirom may be an effective treatment option for patients with MASH and moderate to advanced liver fibrosis.

Resmetirom improved fibrosis without worsening of steatohepatitis in 24%-26% of participants compared to 14% for placebo.

Resmetirom may help improve liver fibrosis in patients with MASH without worsening their condition.

The severity of hypothalamic inflammation and gliosis is related to comorbid conditions such as glucose intolerance and insulin resistance.

Understanding these relationships can help in targeting treatment for obesity-related comorbidities.

Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.

Clinicians should monitor for gastrointestinal side effects when prescribing maridebart cafraglutide.

In rheumatoid arthritis (RA), improved disease activity was reported with GLP-1 receptor agonists.

GLP-1 receptor agonists may be beneficial for improving disease activity in RA patients.

The restore diet reduced gut microbiome diversity but enhanced the persistence of L. reuteri strain.

Practitioners should note that while diversity may decrease, specific beneficial strains can be enhanced through targeted dietary interventions.

Adverse measures of body composition in individuals of any weight can also confer increased breast cancer risk.

Practitioners should assess body composition in addition to BMI when evaluating breast cancer risk.

Endothelial dysfunction is associated with hypercholesterolemia and obesity.

Understanding endothelial dysfunction can help in the treatment of CVD risk factors.

Prolonged, intense weight-bearing exercise can increase intestinal permeability but effects are transient.

While intense exercise can temporarily affect gut health, these effects are not long-lasting.

Having a normal body weight does not automatically imply preserved metabolic health.

Practitioners should assess metabolic health beyond just body weight.

There is evidence for the presence of metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) phenotypes.

Understanding these phenotypes can guide personalized treatment approaches.

GLP-1 receptor agonists (GLP-1RAs) are associated with accelerated facial aging and altered skin health.

Clinicians should be aware of the potential for accelerated facial aging in patients treated with GLP-1RAs.

The accelerated facial aging observed in GLP-1RA patients is multifactorial, involving loss of dermal and subcutaneous white adipose tissue.

Understanding the multifactorial nature of aging can guide treatment approaches for affected patients.

Treatment strategies targeting adipose-derived stem cell (ADSC) stimulation may mitigate facial aging effects from GLP-1RAs.

Clinicians may consider ADSC-targeted treatments to improve skin health in patients using GLP-1RAs.